Eisai chief Ivan Cheung 'not worried at all' about Leqembi's full approval

Nicole DeFeudis

Editor

Days after Eisai and Biogen secured an accelerated approval for their Alzheimer’s drug Leqembi, Eisai US chairman and CEO Ivan Cheung is confident about the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Eisai chief Ivan Cheung 'not worried at all' about Leqembi's full approval

Nicole DeFeudis

Editor

Sign up to read this article for free.

Bicycle Therapeutics stock sinks following release of topline data, post-hoc analyses

EMA's committee says expanded label for Lilly's Mounjaro into sleep apnea not necessary

McKinsey hit with a $650M fine for deceiving US about opioid consulting work

CDK4 inhibitors from BeiGene and Pfizer, ALX’s CD47 drug take the stage at SABCS

Xaira hires former Roche exec as CMO; 'Tis the season for retirements at Alnylam, Regeneron

The key to faster, more impactful research? Put patients in the driver’s seat

Ei­sai chief Ivan Che­ung 'not wor­ried at al­l' about Leqem­bi's full ap­proval

Nicole DeFeudis

Editor

Sign up to read this article for free.

Bi­cy­cle Ther­a­peu­tics stock sinks fol­low­ing re­lease of topline da­ta, post-hoc analy­ses

EMA's com­mit­tee says ex­pand­ed la­bel for Lil­ly's Moun­jaro in­to sleep ap­nea not nec­es­sary

McK­in­sey hit with a $650M fine for de­ceiv­ing US about opi­oid con­sult­ing work

CDK4 in­hibitors from BeiGene and Pfiz­er, ALX’s CD47 drug take the stage at SABCS

Xaira hires for­mer Roche ex­ec as CMO; 'Tis the sea­son for re­tire­ments at Al­ny­lam, Re­gen­eron

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

Eisai chief Ivan Cheung 'not worried at all' about Leqembi's full approval

Bicycle Therapeutics stock sinks following release of topline data, post-hoc analyses

EMA's committee says expanded label for Lilly's Mounjaro into sleep apnea not necessary

McKinsey hit with a $650M fine for deceiving US about opioid consulting work

CDK4 inhibitors from BeiGene and Pfizer, ALX’s CD47 drug take the stage at SABCS

Xaira hires former Roche exec as CMO; 'Tis the season for retirements at Alnylam, Regeneron

The key to faster, more impactful research? Put patients in the driver’s seat